Deshkar Sanjeevani Shekhar, Jadhav Monali Shivaji, Shirolkar Satish Vasudeo
Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India - 411018.
Adv Pharm Bull. 2021 Jan;11(1):150-162. doi: 10.34172/apb.2021.016. Epub 2020 Nov 7.
The present research work was designed to formulate and evaluate carbamazepine (CBZ) loaded nanostructured lipid carrier (NLC) based gel for nasal delivery. The NLC formulation of CBZ was prepared by microemulsion technique followed by probe sonication and evaluated for particle size, zeta potential, entrapment efficiency and in vitro drug diffusion. NLC formulation was incorporated into gelling formulation using poloxamer 407 (P407), poloxamer 188 (P188) and mucoadhesive polymer. The effect of concentration of poloxamer 188 (X ), type of mucoadhesive polymer (X ) and concentration of mucoadhesive polymer (X ) on gelling temperature (Y ) and drug diffusion after 8 h (Y ) was studied using Box-Behnken design. anticonvulsant activity of optimized formulation was studied in Wistar rats by maximal electro-convulsion model (MES). The optimized CBZ NLC formulation, with 20% drug loading, 0.5:1 as Precirol:Capmul MCM ratio as lipid phase and 1:3 as Lipid:Smix ratio, resulted in 89.73±0.2% drug entrapment, 55.95±1.09% of drug diffusion after 8 h, particle size of 132.8 nm with polydispersity index of 0.302 and zeta potential of -29.2±6.1 mV. The gel formulation with 20% P407, 5% P188 and 0.2% chitosan was optimized and demonstrated excellent gelling ability, gelling temperature in the range of 30 to 35°C, 42.46% of drug diffusion in 8 h by Fickian diffusion mechanism and 31.34±0.76% of drug permeation through sheep nasal mucosa. anticonvulsant activity in MES model in rat demonstrated significant efficacy (71.95% protection against seizure in extension phase) as compared to plain nasal gel (50.26% protection against seizure in extension phase). NLC based gelling formulation demonstrated its potential for nasal delivery of CBZ with improved anticonvulsant activity.
本研究旨在制备并评价用于鼻腔给药的载卡马西平(CBZ)纳米结构脂质载体(NLC)凝胶。采用微乳技术制备CBZ的NLC制剂,随后进行探头超声处理,并对其粒径、ζ电位、包封率和体外药物扩散进行评价。使用泊洛沙姆407(P407)、泊洛沙姆188(P188)和黏膜黏附聚合物将NLC制剂加入到凝胶制剂中。采用Box-Behnken设计研究泊洛沙姆188浓度(X₁)、黏膜黏附聚合物类型(X₂)和黏膜黏附聚合物浓度(X₃)对胶凝温度(Y₁)和8小时后药物扩散(Y₂)的影响。通过最大电惊厥模型(MES)在Wistar大鼠中研究优化制剂的抗惊厥活性。优化后的CBZ NLC制剂,载药量为20%,脂质相中Precirol与Capmul MCM的比例为0.5:1,脂质与表面活性剂混合液的比例为1:3,药物包封率为89.73±0.2%,8小时后药物扩散率为55.95±1.09%,粒径为132.8 nm,多分散指数为0.302,ζ电位为-29.2±6.1 mV。优化后的凝胶制剂含有20%的P407、5%的P188和0.2%的壳聚糖,具有优异的胶凝能力,胶凝温度在30至35°C范围内,通过菲克扩散机制在8小时内药物扩散率为42.46%,药物透过绵羊鼻黏膜的渗透率为31.34±0.76%。在大鼠MES模型中的抗惊厥活性表明,与普通鼻腔凝胶相比(延长期惊厥保护率为50.26%),该制剂具有显著疗效(延长期惊厥保护率为71.95%)。基于NLC的凝胶制剂显示出其用于鼻腔递送CBZ并提高抗惊厥活性的潜力。